CytomX Therapeutics Dividendes et rachats
Dividende contrôle des critères 0/6
CytomX Therapeutics n'a pas d'antécédents de versement de dividendes.
Informations clés
n/a
Rendement du dividende
-42.1%
Rendement des rachats
| Rendement total pour l'actionnaire | -42.1% |
| Rendement futur des dividendes | n/a |
| Croissance des dividendes | n/a |
| Prochaine date de paiement du dividende | n/a |
| Date ex-dividende | n/a |
| Dividende par action | n/a |
| Ratio de distribution | n/a |
Mises à jour récentes sur les dividendes et les rachats
Pas de mise à jour
Recent updates
Article d’analyse • May 13
Broker Revenue Forecasts For CytomX Therapeutics, Inc. (NASDAQ:CTMX) Are Surging Higher
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders will have a reason to smile today, with the analysts making...Article d’analyse • May 11
Earnings Update: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Just Reported And Analysts Are Boosting Their Estimates
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) defied analyst predictions to release its first-quarter results, which were...
Mise à jour du récit • Apr 23
CTMX: Late-Line Colorectal Cancer Data Will Drive 2026 Repricing Prospects
Analysts have lifted their average price target on CytomX Therapeutics by several dollars into the low to mid teens, citing stronger confidence in late line colorectal cancer data and updated views on the probability of approval for varsetatug masetecan and CX-2051. Analyst Commentary Bullish analysts are reworking their models after the latest Phase 1 expansion data for varsetatug masetecan in late line colorectal cancer and CX-2051 in colon cancer, with several firms lifting price targets into the low to high teens.Mise à jour du récit • Apr 09
CTMX: Late-Line Colorectal Cancer Data Will Shape 2026 Repricing Path
Analysts have nudged the fair value estimate for CytomX Therapeutics to $13.67 from $13.44, citing a wave of higher price targets across the Street following positive Phase 1 expansion data in late line colorectal cancer and updated views on key pipeline assets. Analyst Commentary Street research has shifted meaningfully in recent days, with multiple firms raising price targets and at least one upgrade from a major bank, all keyed to the latest Phase 1 expansion data in late line colorectal cancer and updated views on CytomX Therapeutics' pipeline.Mise à jour du récit • Mar 26
CTMX: Late-Line Colorectal Cancer Data Will Drive 2026 Repricing Thesis
Analysts have lifted their price targets on CytomX Therapeutics by several dollars per share, with the updated fair value estimate moving from $9.00 to about $13.44, citing stronger confidence in late-line colorectal cancer data and higher assumed profitability for key pipeline assets. Analyst Commentary Street research on CytomX Therapeutics has turned more constructive following updated clinical data in late-line colorectal cancer and corporate updates around key pipeline assets such as varsetatug masetecan, also referenced as Varseta-M, and CX-2051.Seeking Alpha • Mar 16
CytomX: The Probody Mask Just Slipped, And Investors Like What They See (Upgrade)
Summary CytomX Therapeutics, Inc. receives a speculative Buy upgrade following promising new mCRC data for lead asset Varseta-M (CX-2051). Varseta-M shows a clear dose response and manageable safety profile with prophylactic measures, supporting the potential for a pivotal trial in 2027. CTMX valuation is highly dependent on Varseta-M in 3L+ mCRC, with risk-adjusted NPV modeled at $894M and a fully diluted fair value estimated at $7.15 per share. Significant dilution risk exists due to funding needs, but mCRC data validates CytomX’s platform, offering optionality for pipeline expansion. Read the full article on Seeking AlphaMise à jour du récit • Mar 11
CTMX: 2026 Colorectal Cancer Milestones Will Support Repricing Thesis
Analyst price targets for CytomX Therapeutics have moved higher by a few dollars, with the latest $2 and $3.50 target increases reflecting reassessments of fair value, updated profit margin assumptions, and a very large future P/E multiple cited by recent Street research. Analyst Commentary Recent Street research on CytomX Therapeutics clusters around higher price targets, fresh coverage and updated profit margin assumptions, all tied to the potential implied by a very large future P/E multiple.
Mise à jour du récit • Feb 25
CTMX: Colorectal Cancer Pipeline Milestones Will Support Future Repricing
Analysts have nudged their price targets on CytomX Therapeutics higher by a few dollars, reflecting updated assumptions around slightly firmer revenue trends, a modestly lower profit margin profile, and a higher future P/E multiple in recent research from firms such as Barclays, Guggenheim, and Piper Sandler. Analyst Commentary Bullish analysts are framing the recent price target moves as a reflection of refreshed views on CytomX Therapeutics’ ability to execute on its plan, support revenue trends, and justify a higher P/E multiple over time.Mise à jour du récit • Feb 11
CTMX: 2026 Colorectal Cancer Milestones Will Drive Upside Repricing Potential
Analysts have lifted their price targets on CytomX Therapeutics by a few dollars, citing updated fair value assumptions to about $9.00, modest tweaks to projected revenue declines and profit margins, and a higher assumed future P/E multiple. Analyst Commentary Recent Street research on CytomX Therapeutics has centered on modestly higher price targets and updated assumptions for fair value, revenue trends, and profit margins, along with a higher assumed future P/E multiple.Article d’analyse • Jan 28
What CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) 35% Share Price Gain Is Not Telling You
Despite an already strong run, CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shares have been powering on, with a gain of...Mise à jour du récit • Jan 27
CTMX: Colorectal Cancer Milestones And Index Additions Will Support Future Repricing
Narrative Update The analyst price target for CytomX Therapeutics has moved modestly higher to about US$10.00 per share, as analysts factor in slightly better profit margin expectations and a somewhat lower implied future P/E multiple following recent bullish initiation and target raises from several firms. Analyst Commentary Recent research updates point to a more constructive stance on CytomX Therapeutics, with bullish analysts assigning higher price targets and initiating coverage with a positive angle.Mise à jour du récit • Jan 11
CTMX: Colorectal Cancer Data Will Support Stronger Confidence In Lead Program
Analysts have updated their price target on CytomX Therapeutics to US$7, with the shift tied to renewed confidence in CX-2051 after recent colorectal cancer data highlighted how challenging objective responses are in this setting and how the program still stands out to many on the Street. Analyst Commentary Bullish analysts are leaning into the idea that CX-2051 could be differentiated in colorectal cancer, especially after recent Phase 2 data from another company underscored how difficult it is to achieve objective responses in this setting.Mise à jour du récit • Dec 20
CTMX: Colorectal Cancer Data Will Drive Stronger Confidence In Lead Pipeline
Analysts have raised their price target on CytomX Therapeutics, lifting estimated fair value from about $8.00 to roughly $9.80 per share. They cite growing confidence in the risk to benefit profile and blockbuster potential of CX 2051, supported by recent colorectal cancer data comparisons and stronger projected profit margins despite a higher discount rate.Mise à jour du récit • Dec 06
CTMX: 2026 Colorectal Cancer Data Will Drive Upside Repricing Potential
Analysts have modestly raised their price target on CytomX Therapeutics to $7.00, citing growing confidence in the risk reward profile and the blockbuster potential of lead colorectal cancer candidate CX-2051. This follows supportive sector readthroughs and solid cash runway visibility.Mise à jour du récit • Nov 22
CTMX: Upcoming 2026 Data Will Drive New Momentum in Colorectal Cancer
Analysts have increased their price target for CytomX Therapeutics from $6.14 to $7.07 per share, citing growing confidence in the risk-to-benefit profile and blockbuster potential of the company's lead clinical program. This adjustment is based on recent industry data and supportive coverage.Article d’analyse • Nov 13
Analysts Just Shaved Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Forecasts Dramatically
Today is shaping up negative for CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders, with the analysts delivering a...Mise à jour du récit • Nov 05
CTMX: Clinical Momentum Will Drive Shares Higher Despite Recent Safety Concerns
Analysts have modestly increased their price target on CytomX Therapeutics to $6.14 per share, citing ongoing enthusiasm for the CX-2051 program. They also point to reinforced confidence following recent clinical updates and the initiation of coverage.Mise à jour du récit • Oct 22
Analyst Commentary Signals Renewed Optimism as CytomX Therapeutics Receives Higher Price Target
Analysts have increased their fair value price target for CytomX Therapeutics from $5.75 to $6.14 per share. This change reflects growing optimism for CX-2051's clinical potential and resilient investor sentiment despite recent safety updates.Article d’analyse • Oct 18
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Soars 66% But It's A Story Of Risk Vs Reward
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders would be excited to see that the share price has had a great...Article d’analyse • Aug 14
Not Many Are Piling Into CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Yet As It Plummets 26%
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders won't be pleased to see that the share price has had a very...Mise à jour du récit • Aug 11
Late-Stage Trials And Partnerships Will Advance Precision Medicine Despite Setbacks
CytomX Therapeutics’ consensus price target has increased notably, driven by a substantially higher expected P/E despite a decline in net profit margin, resulting in a revised fair value of $5.75 per share. What's in the News First patient dosed with CX-801 in combination with KEYTRUDA in a Phase 1 dose escalation study for metastatic melanoma.Article d’analyse • Jun 18
Here's Why We Think CytomX Therapeutics (NASDAQ:CTMX) Is Well Worth Watching
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Article d’analyse • May 20
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders would be excited to see that the share price has had a great...Article d’analyse • May 16
CytomX Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) just released its quarterly report and things are looking bullish. Statutory...Article d’analyse • Apr 05
Revenues Working Against CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Share Price Following 26% Dive
Unfortunately for some shareholders, the CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) share price has dived 26% in the...
Nouveau récit • Feb 09
Advancements In CX-904 And CX-2051 May Drive Future Revenue Amid Funding Uncertainties
Multiple clinical readouts in 2025 could boost shareholder value and future revenue via new drug approvals.Article d’analyse • Feb 04
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shares have had a horrible month, losing 26% after a relatively good period...Article d’analyse • Dec 17
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Bounce 26% But Its Business Still Trails The Industry
Those holding CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shares would be relieved that the share price has rebounded 26...Article d’analyse • Oct 26
Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues
With a price-to-sales (or "P/S") ratio of 0.7x CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) may be sending very bullish...Seeking Alpha • Jul 15
CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments
Summary CytomX Therapeutics develops innovative oncology treatments using its Probody platform, creating conditionally activated biologics that increase drug efficiency and reduce side effects. Strategic partnerships with leading companies like Amgen, Astellas, and Bristol Myers Squibb leverage CTMX's Probody platform for drug development. The pipeline includes early-stage drugs CX-904, CX-2051, and CX-801, with preclinical programs. CTMX has a short cash runway and potential dilution risks in the next few years. I ultimately rate CTMX a “hold” due to balanced positives and negatives, but I think it's worth adding to your watchlist. Read the full article on Seeking AlphaArticle d’analyse • Jun 15
The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%
The CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) share price has fared very poorly over the last month, falling by a...Stabilité et croissance des paiements
Récupération des données sur les dividendes
Dividende stable: Données insuffisantes pour déterminer si les dividendes par action de CTMX ont été stables dans le passé.
Dividende croissant: Données insuffisantes pour déterminer si les paiements de dividendes de CTMX ont augmenté.
Rendement des dividendes par rapport au marché
| CytomX Therapeutics Rendement des dividendes par rapport au marché |
|---|
| Segment | Rendement du dividende |
|---|---|
| Entreprise (CTMX) | n/a |
| 25% du marché (US) | 1.4% |
| 25% du marché (US) | 4.3% |
| Moyenne du secteur (Biotechs) | 2.4% |
| Analyste prévisionnel (CTMX) (jusqu'à 3 ans) | n/a |
Dividende notable: Impossible d'évaluer le rendement des dividendes de CTMX par rapport aux 25 % les moins bien payés par les actionnaires, car la société n'a signalé aucun versement récent.
Dividende élevé: Impossible d'évaluer le rendement des dividendes de CTMX par rapport aux 25 % des principaux payeurs de dividendes, car la société n'a signalé aucun versement récent.
Bénéfice distribué aux actionnaires
Couverture des revenus: Données insuffisantes pour calculer le ratio de distribution de CTMX afin de déterminer si les dividendes versés sont couverts par les bénéfices.
Paiement en espèces aux actionnaires
Couverture des flux de trésorerie: Impossible de calculer la durabilité des dividendes car CTMX n'a signalé aucun versement.
Découvrir des entreprises qui versent des dividendes élevés
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/22 23:18 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
CytomX Therapeutics, Inc. est couverte par 19 analystes. 8 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Ying Huang | BofA Global Research |